anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
NeuroBo Pharmaceuticals · regulatory-filing

NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides

30 pages · 5 arc beats · 2 loops

Regulatory-Filing Download JSON
Unlock

NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides

NeuroBo Pharmaceuticals · 2022-10
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON
Narrative range 28 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 7 hits
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides · 2 hits 100% 1/1 slides Solution 13 slides 100% 13/13 slides 100% 13/13 slides · 76 hits
— 0/13 slides
38.5% 5/13 slides 15.4% 2/13 slides 100% 13/13 slides · 25 hits 100% 13/13 slides Market Size 1 slides 100% 1/1 slides 100% 1/1 slides · 7 hits
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides · 2 hits 100% 1/1 slides Product 12 slides 100% 12/12 slides 100% 12/12 slides · 71 hits
— 0/12 slides
33.3% 4/12 slides 16.7% 2/12 slides 100% 12/12 slides · 24 hits 100% 12/12 slides Financials 1 slides 100% 1/1 slides 100% 1/1 slides · 3 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides
— 0/1 slides

Slide inventory

30
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detail
02
other
Open slide detail
03
front_matter
Open slide detail
04
The slide details a strategic partnership involving equity investment and asset licensing.establish_context
Open slide detail
05
Includes details on upfront payments, private placement, and milestone/royalty structures.summarize
Open slide detail
06
The slide uses a Gantt-style visualization to map drug development stages against specific clinical indications and future catalysts.plan_implementation
Open slide detail
07
NASH (Non-Alcoholic Steatohepatitis); IND (Investigational New Drug); MAD (Multiple Ascending Dose); SAD (Single Ascending Dose).plan_implementation
Open slide detail
08
The slide serves as a title or introductory page for a specific drug candidate.establish_context
Open slide detailBeat · SolutionLoop · Quick Win Big Bet
09
Includes definitions of acronyms and citations for preclinical studies.summarize
Open slide detailBeat · SolutionLoop · Quick Win Big Bet
10
Study methodology involves 10-week treatment on high fat/fructose/CHO diet.analyze_data
Open slide detailBeat · SolutionLoop · Quick Win Big Bet
11
Study design timeline included; statistical significance noted for treatment groups.analyze_data
Open slide detailBeat · SolutionLoop · Quick Win Big Bet
12
Includes definitions for abbreviations and source citations.analyze_data
Open slide detailBeat · SolutionLoop · Quick Win Big Bet
13
NASH (Non-Alcoholic Steatohepatitis); NAFLD (Non-Alcoholic Fatty Liver Disease); T2DM (Type 2 Diabetes Mellitus); FPFV (First Patient First Visit); LPLV (Last Pestablish_context
Open slide detailBeat · SolutionLoop · Quick Win Big Bet
14
Company branding slide for a specific drug candidate.establish_context
Open slide detailBeat · SolutionLoop · Quick Win Big Bet
15
The slide uses a hub-and-spoke diagram to illustrate the systemic effects of oxyntomodulin.establish_context
Open slide detailBeat · SolutionLoop · Quick Win Big Bet
16
Data from preclinical study in HF-DIO mice.analyze_data
Open slide detailBeat · SolutionLoop · Quick Win Big Bet
17
The slide highlights that DA-1726 efficacy is likely due to dual GLP1R/GCGR agonism.analyze_data
Open slide detailBeat · SolutionLoop · Quick Win Big Bet
18
Study uses male DIO-NASH mice with 30-week GAND feeding and 9-week treatment regimen.analyze_data
Open slide detailBeat · SolutionLoop · Quick Win Big Bet
19
Includes study methodology timeline and statistical significance markers.analyze_data
Open slide detailBeat · SolutionLoop · Quick Win Big Bet
20
NASH (Non-Alcoholic Steatohepatitis); MAD (Multiple Ascending Dose); SAD (Single Ascending Dose); PK (Pharmacokinetic); PD (Pharmacodynamic); FPFV (First Patiensummarize
Open slide detailBeat · SolutionLoop · Quick Win Big Bet
21
transition
Open slide detail
22
Includes a bar chart for NASH diagnosis and a funnel diagram for Obesity patient progression.size_opportunity
Open slide detailBeat · ProblemLoop · Cost Of Inaction
23
compare_peers
Open slide detail
24
The slide highlights rapid adoption compared to Saxenda and notes supply chain issues impacting Q4'21 and H1'22.quantify_opportunity
Open slide detail
25
The slide uses a 'before-after' style comparison to show the potential market cap uplift for NeuroBo's assets compared to current peer valuations.compare_peers
Open slide detail
26
Includes footnotes regarding anti-dilution provisions and Dong-A license agreement terms.analyze_data
Open slide detailBeat · Financials
27
other
Open slide detail
28
The slide details the IP ownership status and patent expiration timelines for two specific drug candidates.establish_context
Open slide detail
29
summarize
Open slide detail
30
front_matter
Open slide detail